Zoetis (ZTS) Competitors $152.52 +1.61 (+1.07%) As of 04/24/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ZTS vs. MRK, PFE, BMY, RPRX, CORT, JAZZ, PRGO, SUPN, PCRX, and OMERShould you be buying Zoetis stock or one of its competitors? The main competitors of Zoetis include Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Royalty Pharma (RPRX), Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), and Omeros (OMER). These companies are all part of the "pharmaceuticals" industry. Zoetis vs. Merck & Co., Inc. Pfizer Bristol-Myers Squibb Royalty Pharma Corcept Therapeutics Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Pacira BioSciences Omeros Merck & Co., Inc. (NYSE:MRK) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, community ranking, media sentiment, valuation, profitability and analyst recommendations. Does the media refer more to MRK or ZTS? In the previous week, Merck & Co., Inc. had 30 more articles in the media than Zoetis. MarketBeat recorded 83 mentions for Merck & Co., Inc. and 53 mentions for Zoetis. Zoetis' average media sentiment score of 1.16 beat Merck & Co., Inc.'s score of 1.10 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merck & Co., Inc. 55 Very Positive mention(s) 6 Positive mention(s) 13 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Zoetis 38 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in MRK or ZTS? Merck & Co., Inc. received 79 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.96% of users gave Zoetis an outperform vote while only 66.78% of users gave Merck & Co., Inc. an outperform vote. CompanyUnderperformOutperformMerck & Co., Inc.Outperform Votes99566.78% Underperform Votes49533.22% ZoetisOutperform Votes91677.96% Underperform Votes25922.04% Is MRK or ZTS a better dividend stock? Merck & Co., Inc. pays an annual dividend of $3.24 per share and has a dividend yield of 4.1%. Zoetis pays an annual dividend of $2.00 per share and has a dividend yield of 1.3%. Merck & Co., Inc. pays out 48.1% of its earnings in the form of a dividend. Zoetis pays out 36.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 14 consecutive years and Zoetis has increased its dividend for 14 consecutive years. Is MRK or ZTS more profitable? Zoetis has a net margin of 26.86% compared to Merck & Co., Inc.'s net margin of 26.67%. Zoetis' return on equity of 53.82% beat Merck & Co., Inc.'s return on equity.Company Net Margins Return on Equity Return on Assets Merck & Co., Inc.26.67% 45.35% 17.36% Zoetis 26.86%53.82%18.86% Do analysts rate MRK or ZTS? Merck & Co., Inc. currently has a consensus target price of $111.13, suggesting a potential upside of 39.03%. Zoetis has a consensus target price of $214.40, suggesting a potential upside of 40.57%. Given Zoetis' stronger consensus rating and higher possible upside, analysts clearly believe Zoetis is more favorable than Merck & Co., Inc..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merck & Co., Inc. 0 Sell rating(s) 12 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 2.59Zoetis 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.08 Do institutionals & insiders believe in MRK or ZTS? 76.1% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 0.1% of Merck & Co., Inc. shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation & earnings, MRK or ZTS? Merck & Co., Inc. has higher revenue and earnings than Zoetis. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerck & Co., Inc.$64.17B3.14$17.12B$6.7311.88Zoetis$9.26B7.35$2.49B$5.4727.88 Which has more risk and volatility, MRK or ZTS? Merck & Co., Inc. has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. SummaryZoetis beats Merck & Co., Inc. on 14 of the 21 factors compared between the two stocks. Get Zoetis News Delivered to You Automatically Sign up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZTS vs. The Competition Export to ExcelMetricZoetisPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$68.05B$6.59B$5.41B$18.86BDividend Yield1.33%3.21%5.44%4.15%P/E Ratio27.887.0522.2432.41Price / Sales7.35273.45397.2428.58Price / Cash22.2665.6738.2017.53Price / Book14.326.506.844.44Net Income$2.49B$142.50M$3.20B$1.02B7 Day Performance2.61%8.32%5.79%3.35%1 Month Performance-5.44%-5.61%-4.29%-5.48%1 Year Performance-0.55%0.11%17.99%4.28% Zoetis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZTSZoetis4.5467 of 5 stars$152.52+1.1%$214.40+40.6%+1.1%$68.05B$9.26B27.8813,800Analyst RevisionPositive NewsMRKMerck & Co., Inc.5 of 5 stars$77.22-1.0%$115.50+49.6%-37.1%$194.73B$64.17B11.4769,000Earnings ReportAnalyst ForecastAnalyst RevisionPositive NewsPFEPfizer4.9993 of 5 stars$21.95-0.9%$31.07+41.6%-13.2%$124.49B$63.63B15.5783,000Upcoming EarningsDividend AnnouncementAnalyst ForecastAnalyst RevisionBMYBristol-Myers Squibb4.7645 of 5 stars$48.52-1.4%$57.67+18.9%-0.4%$98.73B$48.30B-10.9834,300Earnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionRPRXRoyalty Pharma4.6002 of 5 stars$32.15-1.4%$42.50+32.2%+14.5%$18.53B$2.26B22.1780Dividend AnnouncementPositive NewsCORTCorcept Therapeutics4.4997 of 5 stars$62.05-0.3%$143.25+130.9%+219.4%$6.55B$675.04M49.25300Upcoming EarningsPositive NewsJAZZJazz Pharmaceuticals4.921 of 5 stars$99.89-2.8%$187.71+87.9%+0.6%$6.07B$4.07B14.073,200Upcoming EarningsPositive NewsPRGOPerrigo4.8581 of 5 stars$24.14-4.7%$33.00+36.7%-20.4%$3.29B$4.37B-20.638,900Positive NewsSUPNSupernus Pharmaceuticals3.0897 of 5 stars$30.08-2.2%$36.00+19.7%+3.6%$1.68B$661.82M28.11580PCRXPacira BioSciences1.905 of 5 stars$26.10+5.9%$26.67+2.2%+0.4%$1.21B$700.97M-12.86720Positive NewsOMEROmeros3.3656 of 5 stars$6.63-2.2%$22.50+239.4%+140.1%$384.96MN/A-2.87210 Related Companies and Tools Related Companies Merck & Co., Inc. Alternatives Pfizer Alternatives Bristol-Myers Squibb Alternatives Royalty Pharma Alternatives Corcept Therapeutics Alternatives Jazz Pharmaceuticals Alternatives Perrigo Alternatives Supernus Pharmaceuticals Alternatives Pacira BioSciences Alternatives Omeros Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ZTS) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zoetis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zoetis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZTS Stock Free ZTS Stock Alerts